Flynn counsel bemoans CMA treatment

A Flynn Pharma lawyer today argued the UK antitrust enforcer’s phenytoin excessive pricing decision wrongly suggested the company misled the UK’s Department of Health, and did not properly assess evidence of a 2012 meeting between the company and the health ministry.


Get unlimited access to all Global Competition Review content